This content is machine translated Psoriasis: therapy with biologics and TYK-2-i Progress assessments based on current long-term and real-world data A broad spectrum of systemic agents is now available for the treatment of moderate to severe psoriasis. At this year’s DDG congress “Dermatology compact + practical”, various studies were presented...…
View Post 4 min This content is machine translated TYK2 inhibition in psoriasis What’s new? The JAK-STAT pathway mediates a variety of proinflammatory responses through Janus kinases (JAK)1-3 andtyrosine kinase-2 (TYK2).Deucravacitinib selectively inhibits TYK2 and was shown to be effective and safe in patients with…
View Post 3 min This content is machine translated Plaque psoriasis TYK2 inhibition shows great therapeutic potential Psoriasis is nowadays understood as a systemic disease, which is based on chronic inflammation. Research into the etiopathogenesis, as well as the establishment of new active substances, is progressing rapidly.…
